Experimental HIV Drugs
Experimental HIV Drugs
CROI 2015: HIV Attachment Inhibitor BMS-663068 Shown Safe and Effective in Phase 2b Study
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 03 March 2015 00:00
- Written by Liz Highleyman
Bristol-Myers Squibb's BMS-663068 or fostemsavir, a first-in-class HIV attachment inhibitor that stops the virus from binding to and entering cells, was well-tolerated and demonstrated good antiviral activity in a study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle. Related research showed that BMS-663068 can safely be taken with antiretrovirals commonly used by treatment-experienced patients. A Phase 3 trial is now underway.
CROI 2015: Tenofovir Alafenamide as Effective but Safer for Kidneys and Bones than TDF
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 February 2015 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF), a new formulation that has lower concentrations in the blood but reaches higher levels in cells, is as effective as the older version, tenofovir disoproxil fumarate (TDF), according to a report at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle. A second study showed that TAF has less detrimental effects on the kidneys and bones compared with TDF. TAF has been submitted for approval in the U.S. and Europe.
CROI 2015: HIV Maturation Inhibitor BMS-955176 Looks Promising In Early Study
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 25 February 2015 00:00
- Written by Liz Highleyman
A second-generation HIV maturation inhibitor, BMS-955176, demonstrated good safety and high potency, including activity against viral strains that were not susceptible to an earlier drug in this class, researchers reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) taking place this week in Seattle.
CROI 2015: Putting On Too Much Weight After Starting ART Increases Chronic Inflammation
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 27 February 2015 00:00
- Written by Theo Smart
A return to normal weight after starting antiretroviral therapy (ART) can be beneficial for very sick, underweight individuals living with HIV -- but further weight gain appears to increase markers of inflammation associated with metabolic complications and poorer survival, according to a study reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) this week in Seattle.
Gilead and Janssen Announce Deal to Develop New TAF Single-Tablet Regimens
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 12 January 2015 00:00
- Written by Gilead and Janssen
Gilead Sciences and Janssen R&D announced an agreement in late December to develop antiretroviral coformulations containing Gilead's novel tenofovir alafenamide (TAF) formulation and emtricitabine plus Janssen's HIV protease inhibitor darunavir (Prezista) or NNRTI rilpivirine (Edurant).
Web Design and Development by